Geriatric Ward, The First Hospital of Harbin, Harbin, China.
Department of Emergency, Affiliated Hospital of Sichuan Nursing Vocational College (The Third People's Hospital of Sichuan Province), Chengdu, China.
Medicine (Baltimore). 2022 Aug 12;101(32):e30049. doi: 10.1097/MD.0000000000030049.
Diabetes mellitus is a spectrum of metabolic disorders characterized by hyperglycemia and shows a growing global public health problem in the elderly. Resveratrol presents antiaging, anti-inflammatory, antitumor antioxidant, and cardioprotective activities. The purpose of this study was to investigate the ameliorative effects of resveratrol on blood glucose, insulin metabolism, lipid profile, renal function, inflammation, and nutrient sensing systems in the elderly patients with type 2 diabetes mellitus.
The study is a single-blind, parallel-group, randomized controlled clinical trial consisting of a 6-month treatment period. A total of 472 elderly patients with type 2 diabetes mellitus were enrolled, and included participants will be randomized into 2 groups: resveratrol (n = 242) and placebo (n = 230). The clinical efficacy and changes in clinical parameters in each group will be measured at the indicated time. Clinical parameters included blood glucose, insulin resistance index, blood lipid index, proinflammatory cytokines, renal function, and nutrient sensing systems.
Resveratrol treatment greatly improved glucose metabolism, insulin tolerance, and insulin metabolism compared to placebo. Resveratrol relieved symptoms through enhancing nutrient sensing systems, which in turn reduced production and activity of glucose-6-phosphatase. Compared with placebo, resveratrol treatment significantly decreased proinflammatory cytokines glycated hemoglobin/hemoglobin A1c, interleukin-6, tumor necrosis factor-alpha, and interleukin-1beta in the elderly diabetes. Resveratrol treatment decreased blood glucose parameters, improved the lipid profile (total cholesterol, low-density lipoprotein, high-density lipoprotein, and triglycerides), and renal function compared to placebo.
In conclusion, resveratrol treatment improves inflammation, renal function, blood glucose parameters, inflammation, insulin resistance, and nutrient sensing systems in the elderly patients with type 2 diabetes mellitus, indicating resveratrol may be a potential therapeutic drug for the treatment of the elderly patients with type 2 diabetes mellitus.
糖尿病是一种代谢紊乱的疾病,其特征是高血糖,并在老年人中呈现出日益严重的全球公共卫生问题。白藜芦醇具有抗衰老、抗炎、抗肿瘤、抗氧化和心脏保护作用。本研究旨在探讨白藜芦醇对老年 2 型糖尿病患者血糖、胰岛素代谢、血脂谱、肾功能、炎症和营养感应系统的改善作用。
本研究为单盲、平行组、随机对照临床试验,包括 6 个月的治疗期。共纳入 472 例老年 2 型糖尿病患者,将纳入的患者随机分为两组:白藜芦醇(n=242)和安慰剂(n=230)。在规定的时间测量每组的临床疗效和临床参数变化。临床参数包括血糖、胰岛素抵抗指数、血脂指数、促炎细胞因子、肾功能和营养感应系统。
与安慰剂相比,白藜芦醇治疗显著改善了葡萄糖代谢、胰岛素耐量和胰岛素代谢。白藜芦醇通过增强营养感应系统缓解症状,从而降低葡萄糖-6-磷酸酶的产生和活性。与安慰剂相比,白藜芦醇治疗显著降低了老年糖尿病患者的促炎细胞因子糖化血红蛋白/血红蛋白 A1c、白细胞介素-6、肿瘤坏死因子-α和白细胞介素-1β。与安慰剂相比,白藜芦醇治疗可降低血糖参数,改善血脂谱(总胆固醇、低密度脂蛋白、高密度脂蛋白和甘油三酯)和肾功能。
总之,白藜芦醇治疗可改善老年 2 型糖尿病患者的炎症、肾功能、血糖参数、炎症、胰岛素抵抗和营养感应系统,表明白藜芦醇可能是治疗老年 2 型糖尿病患者的潜在治疗药物。